Small-molecule CDMOs face challenges like funding cuts, supply chain disruptions, and growing demand, yet they remain essential in balancing supply and demand, driving innovation, and improving patient outcomes. This article discusses that in order to thrive, they must continue embracing innovation, streamlining operations, and ensuring flexibility and scalability in their production processes, while focusing on patient-centric drug discovery and integrating advanced manufacturing technologies.
